ePrivacy and GPDR Cookie Consent by Cookie Consent

Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics


Nov. 12, 2019


A phase I basket trial of a novel KRAS G12C inhibitor (MRTX849) has delivered partial responses for patients with lung and colorectal cancer (1 each to date).